Erytech Pharma S.A.
ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 21, 2019
LYON, France, May 31, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma
(Euronext Paris: ERYP – Nasdaq: ERYP),
a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells,
today announced that
the availability of the documents for its Annual General Meeting to be held on June 21, 2019
ERYTECH’s shareholders are hereby informed of the Annual General Meeting which will take place on June 21, 2019 at 09:30am CET at the Centre Edouard VII, 23 Rue Édouard VII, 75009 Paris (FRANCE).
The meeting and convening notice (l'avis de réunion valant convocation ) containing the detailed agenda, draft resolutions as well as instructions to participate and vote for the Annual General Meeting was published in the French official legal announcement publication “Bulletin des Annonces Légales Obligatoires ” (BALO) N°59 of May 17, 2019 and in “l’ESSOR” n# ES173392 on May 31, 2019.
Pursuant to applicable French laws and regulations, the preparatory documents and information for the Annual General Meeting are available and posted on the Company’s website www.erytech.com , under the section « Investors / Shareholders Meeting / General Meeting 2019 ».
About ERYTECH: www.erytech.com
ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs.
ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is also developing erymethionase, which consists of methionine-gamma-lyase encapsulated in red blood cells to target methionine-dependent cancers.
ERYTECH produces product candidates at its GMP-approved manufacturing site in Lyon, France, and at the American Red Cross in Philadelphia, USA. A large-scale GMP manufacturing facility has recently completed construction in Princeton, New Jersey, USA.
ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
CFO & COO
Mathilde Bohin / Louis-Victor Delouvrier
|+33 4 78 74 44 38
|+33 1 44 71 98 52
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
TDC A/S3.9.2019 12:51:36 CEST | Press release
TDC A/S and DKT Holdings ApS: Updated financial calendar for 2019
Jobindex A/S20.8.2019 08:42:29 CEST | Pressemeddelelse
2. kvartal 2019: Væksten på jobmarkedet er gået i stå
Bizagi17.7.2019 18:02:02 CEST | Press release
Bizagi goes from Stealth to Hyper Growth Delivering Digital Transformation for World Leading Brands
Erytech Pharma S.A.16.7.2019 22:02:00 CEST | Press release
ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 21, 2019
WSO215.7.2019 15:02:38 CEST | Press release
WSO2 Introduces WSO2 API Microgateway 3.0 to Simplify Creating, Deploying and Securing APIs in Microservice Environments
Lubrizol15.7.2019 08:01:33 CEST | Press release
Lubrizol Acquires Bavaria Medizin Technologie GmbH
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom